Test Price
2,800 AED✅ Home Collection Available
RANBP2 Gene Sequencing for Acute Necrotizing Encephalopathy Type 1 – NGS Genetic Test in Dubai
Executive Summary & Core Metrics
- Diagnostic Accuracy: 99.9% sensitivity via ISO‑accredited next‑generation sequencing (NGS) on the Illumina NextSeq 2000 platform.
- Sample Collection: VIP mobile phlebotomy and temperature‑controlled cold‑chain home collection available daily from 8 AM to 11 PM. Alternatively, samples accepted at our Dubai Healthcare City laboratory.
- Turnaround Time: 3–4 weeks from sample receipt to final clinical report.
- Clinical Support: Post‑test telephonic interpretation by a consultant medical geneticist included with every report.
- Insurance & Billing: Direct billing verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
The RANBP2 NGS test analyses the entire coding region and conserved splice‑site boundaries of the RANBP2 gene to identify pathogenic and likely pathogenic variants associated with Acute Necrotizing Encephalopathy Type 1 (ANE1). This molecular confirmation is essential for accurate diagnosis, prognosis, recurrence risk counselling, and informed family planning. Sequencing is performed on the Illumina NextSeq 2000 platform with 150 bp paired‑end reads, achieving ≥50× mean depth of coverage across all target regions. Bioinformatic analysis adheres to ACMG/AMP variant interpretation guidelines.
| Feature | DNA Labs UAE – RANBP2 NGS Test | Traditional Single‑Gene Sequencing |
|---|---|---|
| Methodology | Next‑generation sequencing – full gene coverage including intronic boundaries | Sanger sequencing – limited to selected exons |
| Turnaround Time | 3–4 weeks | 6–8 weeks |
| Detection Rate for Known RANBP2 Variants | >99% | ~85% (misses deep intronic and copy‑number variants) |
| Cost (AED) | 2,800 | 1,850 (may require reflex testing) |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403 – “Acute Necrotizing Encephalopathy Type 1 is a rare but severe neuroinflammatory disorder with a well‑established genetic basis. NGS‑based RANBP2 analysis provides definitive molecular evidence that informs acute management, recurrence risk, and family screening. Every result must be interpreted in conjunction with the clinical phenotype and neuroimaging findings; a negative result does not exclude all genetic causes of encephalopathy. I recommend that families consult a clinical geneticist to fully understand the implications before and after testing.”
Advisory – Medication & Clinical Precautions
Do not discontinue, alter, or initiate any prescribed medication—especially anticonvulsants, immunomodulators, or corticosteroids—without explicit guidance from your treating physician. Test results may take several weeks; continue all current therapies as directed until your doctor advises otherwise.
Exclusion Criteria & Emergency Red Flags
- Active systemic infection, febrile illness, or immunocompromised state may require deferral of sample collection until clinically stable.
- Patients receiving high‑dose corticosteroid therapy or disease‑modifying immunomodulators must obtain written physician clearance prior to blood draw.
- Emergency signs: Sudden high fever, new‑onset seizures, severe headache, altered consciousness, or focal neurological deficits—seek emergency medical attention immediately. Do not wait for test results.
Patient FAQ & Clinical Guidance
1. What is the RANBP2 genetic test and why is it important?
This next‑generation sequencing test detects disease‑causing variants in the RANBP2 gene to confirm a diagnosis of Acute Necrotizing Encephalopathy Type 1. Molecular confirmation enables targeted treatment decisions, accurate recurrence risk assessment for families, and informed genetic counselling.
2. What sample is required and how is it collected?
A peripheral whole blood sample (3–5 mL in an EDTA tube), extracted genomic DNA (2 µg at >50 ng/µL), or a dried blood spot on an FTA card is required. Collection is performed via VIP mobile phlebotomy at your home in Dubai or at our accredited laboratory in Dubai Healthcare City. Samples are transported under ISO‑certified cold‑chain conditions. Sequencing is completed within 3–4 weeks.
3. Does health insurance in the UAE cover this genetic test?
Many UAE health insurance plans provide coverage for medically indicated genetic testing following pre‑authorization. Our billing team verifies your eligibility and manages the direct billing process—simply send your policy details via WhatsApp to +971 54 548 8731 for a rapid coverage check.
4. How do I interpret a positive or negative result?
A positive result identifies a pathogenic variant in RANBP2 consistent with ANE1. A negative result reduces the likelihood of ANE1 but does not exclude all genetic encephalopathies. All reports include a telephonic consultation with our consultant medical geneticist, who will explain the findings and recommend appropriate next steps in the context of your clinical history.
UAE Regulatory & Data Privacy Adherence
Data Protection & Health Information Governance
All genetic data generated during the performance of this test is processed, stored, and transmitted in full compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent and clinical safety protocols adhere to Federal Decree‑Law No. 4 of 2016 on Medical Liability. No genetic information is shared with third parties without explicit written consent. DNA Labs UAE maintains ISO 9001:2015 certification (Cert. INT/EGQ/2509DA/3139) and operates under DHA Facility License No. 1143.
Clinical & Logistical Metadata
| Test Name | RANBP2 Gene Sequencing for Acute Necrotizing Encephalopathy Type 1 – NGS |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 weeks from sample receipt |
| Sample Type / Matrix | Peripheral whole blood (EDTA), extracted genomic DNA, or dried blood spot on FTA card. VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection available daily from 8 AM to 11 PM. |
| Methodology Used | Next‑Generation Sequencing (Illumina NextSeq 2000, 150 bp paired‑end, ≥50× mean depth) with ACMG/AMP variant interpretation |
| ICD-10-CM Code | G04.8 |
| LOINC Code | 82267-6 |
| DHA Facility License & Laboratory Address | DHA Facility License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians